Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 347 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Immunotherapy Effective in Alveolar Soft Part Sarcoma January 9, 2019 FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... November 15, 2022 Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of... April 27, 2023 FDA Approves Belzutifan for Advanced Renal Cell Carcinoma January 19, 2024 Load more HOT NEWS How to Provide Support as a Long-Distance Cancer Caregiver Detecting multiple cancers with a ‘simple’ blood test: Where are we? Capmatinib Shows Activity in Advanced NSCLC with a MET Exon 14... ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical...
